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Epithelial Immunization Induces Polyfunctional CD8 T Cells and
Optimal Mousepox Protection
Adam R. Hersperger,a,b Nicholas A. Siciliano,a Brian C. DeHaven,a Adam E. Snook,a Laurence C. Eisenlohra
Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USAa; Department of Biology, Albright
College, Reading, Pennsylvania, USAb
We assessed several routes of immunization with vaccinia virus (VACV) in protecting mice against ectromelia virus (ECTV). By
a wide margin, skin scarification provided the greatest protection. Humoral immunity and resident-memory T cells notwith-
standing, several approaches revealed that circulating, memory CD8 T cells primed via scarification were functionally superior
and conferred enhanced virus control. Immunization via the epithelial route warrants further investigation, as it may also pro-
vide enhanced defense against other infectious agents.
Analogous to the protection of humans against smallpox, vac-cinia virus (VACV) protects mice against ectromelia virus
(ECTV; “mousepox”) (1–4). In this study, we examined whether
the route of immunization with VACV (strain Western Reserve;
1 106 PFU dose) influences the generation of protective immu-
nity in BALB/c mice (females, 6 to 8 weeks old). The following
vaccination routes were chosen: skin scarification (s.s.), intraper-
itoneal (i.p.) inoculation, or subcutaneous (s.c.) injection.
Recent studies have shown that epithelial infection elicits skin
resident-memory T cells (TRM) that are highly effective at control-
ling a homologous, cutaneous virus challenge (5–7). Conse-
quently, we hypothesized that the s.s. vaccination group (s.s.
mice) would most effectively control a dermal (i.e., footpad [f.p.])
ECTV (Moscow strain) challenge given 30 days postimmuniza-
tion. In contrast to the other groups, s.s. mice showed no signs of
morbidity (Fig. 1A) or mortality (Fig. 1B) following a footpad
infection with high-dose ECTV (1 105 PFU).
To determine whether s.s. protects against ECTV infection via a
heterologous route, we challenged groups of vaccinated mice (on day
30 postimmunization) via the intranasal (i.n.) route with the same
dose of ECTV as described above. Although all groups experienced
signs of morbidity, weight loss was significantly less severe in the s.s.
group (Fig. 1C). All s.s. mice survived the i.n. challenge, but 10% of
i.p. mice and 30% of s.c. mice did not (Fig. 1D). Notably, the s.s.
group displayed the lowest virus titers in multiple organs at day 7
postchallenge (Fig. 1E). Additionally, none of the s.s. mice developed
pock lesions, whereas some surviving animals in the i.p. and s.c.
groups developed lesions on the tail or limbs (data not shown).
In general, s.s. mice were the only group of vaccinated animals
in our study that failed to develop pock lesions, regardless of the
route of ECTV challenge. These observations are consistent with
previous reports on monkeypox infection of nonhuman primates
(8–10) in which no pock lesions were observed on animals inoc-
ulated with Dryvax (Wyeth) smallpox vaccine administered by
scarification. However, lesions did materialize in the context of
other vaccination protocols, such as intramuscular (i.m.) injec-
tion of modified vaccinia virus Ankara (MVA) (8), that did not
employ an epithelial route. Therefore, it is plausible that skin TRM,
which are generated by scarification but not i.m. injection, help to
prevent the appearance of lesions, which occur as a consequence
of virus replication in the skin (11).
To explore the protective mechanisms provided by s.s. immu-
nization, we assessed adaptive immune responses within each
group. First, we measured VACV-specific antibody levels in each
vaccination group at day 30 postimmunization. As shown in Fig.
2, vaccination via the i.p. route resulted in the greatest level of
circulating antibody. Interestingly, it has been previously con-
cluded that antibody is the sole correlate of protective immunity
against secondary poxvirus challenge (10, 12–14). Given this prec-
edent, we were surprised to observe that s.s. mice had significantly
lower levels of circulating antibodies than i.p. mice. This apparent
divergence from past studies (10, 12, 13) may be due to differences
in dose or route of challenge. For example, it is possible that anti-
bodies by themselves are sufficient after low-dose challenge with
ECTV (12, 13), but T-cell responses become more critical as the
amount of challenge inoculum increases.
To evaluate poxvirus-specific CD8T-cell (TCD8) responses, we
used a pool of previously identified VACV class I epitopes (15) and
measured five functional parameters (CD107a, gamma interferon
[IFN-], interleukin 2 [IL-2], MIP1, and tumor necrosis factor al-
pha [TNF-]) by using intracellular cytokine staining (ICS) assays.
These ICS assays were carried out as previously described (16, 17),
and anti-CD107a was included at the start of all stimulations to mea-
sure levels of degranulation (18). Our gating strategy and Boolean
analysis were similar to those employed previously (16).
At day 7 postimmunization, we identified VACV-specific
TCD8 in the spleen and blood of all groups. Despite similar mag-
nitudes of total response between groups (Fig. 3A), VACV-spe-
cific TCD8 from s.s. mice displayed an enhanced polyfunctional
profile (Fig. 3B) and higher IFN- expression on a per-cell basis
(Fig. 3C). The two permutations that contributed most to the
observed differences were cells positive for all five functions and
those positive for all measured parameters except IL-2 (Fig. 3D).
There was also significantly higher coexpression of TNF- with
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IFN- among VACV-specific TCD8 from s.s. mice in both the
spleen and blood (Fig. 3E). The higher multifunctional nature of
TCD8 from s.s. mice was maintained into the memory phase (at
day 30) and also during a secondary recall response (Fig. 3F).
Prior work has demonstrated a correlation between control of
HIV replication and the presence of polyfunctional TCD8 (17,
19–21). Since TCD8 primed by scarification displayed higher
functionality, we hypothesized that TCD8 from s.s. mice would
confer greater control of ECTV in vivo. To test this, we purified
total splenic TCD8 from vaccinated mice (n  5, pooled), trans-
ferred 5  106 cells (22) into naive mice, and subsequently in-
fected them with ECTV (3 104 PFU; f.p. route). Stimulation of
cells using the major histocompatibility complex (MHC) class I
peptide pool revealed that equivalent numbers of VACV-specific
TCD8 were transferred across all groups (data not shown). As
shown in Fig. 3G, mice that received TCD8 primed by s.s. achieved
the highest degree of control over ECTV, demonstrating a direct
relationship between virus control and the functional capacity of
antiviral TCD8.
FIG 1 Scarification of VACV elicits optimal control of ECTV regardless of challenge route. (A and B) Groups of naive or vaccinated mice (5 per group) were
challenged with 1 105 PFU of ECTV in the left hind footpad and subsequently monitored for weight loss (A) and mortality (B). (C and D) Groups of naive or
vaccinated mice (10 per group) were challenged with 1 105 PFU of ECTV via the i.n. route and subsequently monitored for weight loss (C) and mortality (D).
(E) Separate cohorts of vaccinated mice (5 per group) were infected with 1 105 PFU of ECTV via the i.n. route. On day 7 postchallenge, the indicated organs
were isolated and levels of ECTV were quantified using standard plaque assays. These data are representative of two independent experiments. UND, undetect-
able. *,P value 0.05; **,P value 0.01. Statistical analysis was performed using GraphPad Prism. Error bars represent the mean and standard error of the mean.
(A to E) For i.p. and s.c. injections, the virus inoculum was given in a total volume of 100 l of 1 PBS. Scarification was performed at the base of the tail using
a 27-gauge needle and a 10-l drop of VACV in 1 PBS.
FIG 2 Immunization via the i.p. route yields the highest levels of circulating
antipoxvirus antibodies. Plasma was isolated by retro-orbital bleeding from
mice that had been immunized with VACV 30 days earlier via the indicated
routes. Levels of circulating antibodies were quantified using plates coated
with VACV at 1  106 PFU per well. Antibody titers were determined by
calculating the 50% effective concentration (EC50) using nonlinear regression
in GraphPad Prism (version 5.0a). Values calculated above or below the dilu-
tion range were set to 1/30 and 1/10,000, respectively. **, P value 0.01; ***,
P value  0.001. The solid black lines represent the mean value within each
group. Statistical analysis was performed using GraphPad Prism. Each data
point represents one individual mouse. Black data points are from one indi-
vidual experiment, and blue data points are from a second independent trial.
Scariﬁcation Yields Highly Functional CD8 T Cells
August 2014 Volume 88 Number 16 jvi.asm.org 9473
 o
n







The ability of s.s. vaccination to generate skin TRM cells has
been of recent interest. As expected, we found in this study that
mice vaccinated by scarification of VACV, which induces poxvi-
rus-specific TRM cells in the skin (5, 7, 23), most effectively con-
trolled a challenge dose of ECTV given via cutaneous inoculation.
However, perhaps less predictably, s.s. mice also demonstrated a
better outcome following heterologous i.n. challenge and most
effectively controlled ECTV in the lungs. Therefore, it appears that
circulating T-cell responses elicited by epithelial infection deserve
consideration in addition to skin-resident populations. Since this
study employed a somewhat virulent strain of VACV, future work
will determine if these results hold true in the context of attenu-
ated vaccine strains, such as MVA or Lister.
In summary, we found that in comparison with other routes,
epithelial inoculation generated circulating TCD8 with superior
ability to secrete multiple cytokines and better control over ECTV
replication in vivo. Importantly, antibody levels alone did not dic-
tate the degree of protection or correlate with full virus control.
Instead, it appears that both antibodies and TCD8 cooperate to
bring about optimal control of a high-dose ECTV challenge.
These findings point toward the importance of investigating the
protective effects of scarification in the context of other patho-
gens.
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FIG 3 Scarification of VACV primes highly functional TCD8 with enhanced antiviral capacity. (A) Response magnitudes, on a percentage basis, to the MHC class I
peptide pool (final concentration of each peptide, 2g/ml) at day 7 in the spleen (5 per group) was calculated by summing across all functional combinations. Note that
the total numbers of virus-specific TCD8 per spleen were similar across the groups as well. (B) TCD8 responses from the spleen (5 per group) and blood (5 per group)
at day 7 were divided into the relative coexpression of all parameters and grouped according to the degree of coexpression. (C) The median fluorescence intensity (MFI)
of IFN- expression was calculated among day 7 TCD8 responses in the spleen. (D) TCD8 responses at day 7 in the spleen were divided into the relative contribution of
each functional combination to the response as a whole. The two permutations that contributed most prominently to the higher polyfunctional response among s.s.
TCD8 are shown. Error bars represent the standard deviation. *, P value 0.05. (E) Flow cytometric plots showing TNF- versus IFN- are shown for representative
TCD8 responses in the spleen. Percentages denote the proportion of IFN-
 cells that are positive or negative for TNF-. (F) The functional profiles are shown for
memory TCD8 responses in the blood (5 per group) or during a secondary recall response in the spleen 5 days (5 per group; day 35 after initial immunization) following
f.p. challenge with 1 105 PFU of ECTV. (A to F) The data are representative of three independent experiments. (G) Bulk splenic TCD8 were negatively selected from
mice (n5, pooled) that had been vaccinated 30 days earlier and then transferred into naive animals. A total of 5106 TCD8 in 100l of sterile 1PBS were transferred
via lateral tail vein injection. Following f.p. ECTV challenge 1 day posttransfer, the indicated organs were isolated at day 7 and viral load was quantified using plaque assays.
The data are representative of two independent experiments. *,P value 0.05. Statistical analysis was performed using GraphPad Prism. Error bars represent the mean
and standard error of the mean.
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